TOVX to trade on post-split basis Dec 2 after reverse stock split
Theriva Biologics announced a 1-for-30 reverse stock split effective Dec 1 to meet NYSE American listing requirements, reducing outstanding shares to approx. 1.5 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed